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Impact of Prospective Screening for Multiple Endocrine Neoplasia 
Type 2 
Robert F. Gagel,* Armen H. Tashjian, Jr, Tim Cummings, Nick Papathanasopoulos, 
and Seymour Reichiin 
Prospective annual screening for hereditary medullary thyroid carcinoma (MTC) in the J-kindred, 
currently a 117-memberfamily with multiple endocrine neoplasia type 2A, began in 1969. During the 
initial screening, 12 patients were found to have MTC. Subsequent screening has detecied C-cell 
abnormalities (C-cell hyperplasia or microscopic MTC) in 22 of 23 addilional family members 
thyroidectomized for abnormal calcium- or pentagastrin-provocative calcitonin (CT) test results. 
Seven of the initial 12 patients thyroidectomized in 1970 to 1971 and 19 of 23 individuals 
thyroidectomized since 1971 remain disease-free by all criteria; three patients thyroidectomized since 
1971 have had clearly abnormal serum CT measurements on one or more provocative tests. The 
significance of these abnormal tesl results is unclear because normal values were obtained when the 
samples were measured in another CT radioimmunoassay. Urine catecholamine abnormalities have 
been detected in 19 family members since 1969, resulting in ten bilateral and eight unilateral 
adrenalectomies. Four of the patients with initial unilateral adrenalectomy required reoperation for a 
pheochromocytoma in the contralateral gland nine to 13 years later. Hyperparathyroidism has not 
been observed in any ofthe family members with early C-cell disease. We conclude that prospective 
screening for hereditary MTC predicts histologic C-cell abnormalities in affected individuals, and 
follow-up ofthese patients provides supportfor the conclusion that early thyroidectomy is curative in 
most patients. (Henry Ford Hosp Med J 1987:35:94-8) 
Prospective screening for hereditary medullary thyroid carcinoma (MTC) began in 1969 when Melvin et al (1,2) 
studied J-kindred members, descendants from a large Swedish 
family affected with this disease (3), to determine whether 
measurement of semm calcitonin (CT) could correctly predict 
the presence of MTC. In their inifial screening of the family, 12 
individuals were found to have abnormal semm CT levels after a 
provocative calcium (Ca) infusion. Thyroidectomy in each 
of these individuals showed bilateral foci of MTC (1). Since the 
initial screening of the family, each unaffected family member 
over the age of five has been screened with a provocative Ca or 
pentagastrin test on a regular basis (annually in most cases) to 
determine whether it is possible to detect hereditary MTC in its 
earliest stages and effect a cure by total thyroidectomy. Previous 
reports from this study have shown that prospective screening 
detects early abnormalities of C-cells prior to the development 
of metastasis (4,5). Members of this kindred also have been 
shown to develop parathyroid abnormalities and adrenal medul-
lary disease including pheochromocytoma (2,4) and adrenal 
medullary hyperplasia (4,6), This report focuses on the clinical 
course of those individuals prospectively screened for the abnor-
malities associated with this syndrome and describes the man-
agement used in this family. 
Patients and Methods 
Screening for MTC 
The J-kindred is a large family (currently 117 members) with 
multiple endocrine neoplasia type 2A (MEN-2A) (2). Pro-
cedures used for the study of CT secretion in this family have 
been described (1,2,4,5). Each pafient over the age of five has 
undergone a yearly Ca (15 mg elemental Ca/kg body weight) or 
pentagastrin (0.5 |xg/kg, administered as an intravenous bolus 
over five seconds) test. Serum CT was measured by radioim-
munoassay (RIA) (7) at appropriate time points as described 
(1,4,5). Basal serum CT concentrations in normal subjects 
ranged from nondetectable to 380 pg/mL; Ca or pentagastrin-
stimulated levels did not exceed 550 pg/mL. Thyroidectomy 
has been recommended if the patient has shown an abnormal CT 
secretory response to at least two separate provocative tests. 
Total thyroidectomy was performed by the method of Crile (8). 
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Histologic techniques for analysis of thyroid tissue and the 
criteria used for diagnosis of C-cell hyperplasia or carcinoma 
have been described (9). 
During the past two years a more sensitive CT RIA has been 
used in addition to the standard assay. The kit for this assay 
(40-2125) was obtained from Nichols Institute Diagnosfics (San 
Juan Capistrano, CA). This assay has a reported sensitivity of 3 
pg/mL, and normal basal values are 3 to 36 pg/mL for men and 2 
to 17 pg/mL for women. After a pentagastrin injection, normal 
stimulated values ranged from 6 to 106 pg/mL in men and 3 to 29 
pg/mL in women. Adrenal medullary function was assessed by 
measurement of urine epinephrine and norepinephrine as de-
scribed (4). Parathyroid hormone and semm Ca were measured 
by the Nichols Institute Reference Laboratories (San Juan Cap-
istrano, CA), using a C-terminal RIA (1974 to 1983) and a mid-
region assay (1984 to 1986). 
Results 
Clinical course of patients with MTC and C-cell hyperplasia 
Thirty-five family members have been thyroidectomized 
since the start of prospective screening in 1969 (Fig 1). The oper-
ative and pathologic findings in the initial 12 patients (mean age 
38.5 years) thyroidectomized between 1969 and 1971 have been 
reported (1,2). All of these patients had bilateral foci of MTC, 
seven of 12 with documented local nodal metastasis. An addi-
tional 23 patients (mean age 11.8 years) have been thyroidec-
tomized since 1971 for the development of abnormal CT levels 
after provocative testing. Histologic examination of the thyroid 
gland showed C-cell hyperplasia in 13 patients, combined mi-
croscopic MTC and C-cell hyperplasia in nine patients, and no 
histologic abnormality in one patient (considered to be a false-
positive test result) (4,5). None of the patients had histologic 
evidence of metastatic disease in local lymph nodes. 
The 12 patients thyroidectomized during the initial screening 
have been followed annually or biannually in most cases (mean 
follow-up period of 14.5 years) with provocative tests (Ca or 
pentagastrin). Three of the 12 patients have died. One died sec-
ondary to metastatic rectal carcinoma (family tree #3, Fig 1), 
and another died from metastatic breast carcinoma (family tree 
#32, Fig 1), although both these patients were thought to have 
metastatic MTC because of persistent elevations of the semm CT 
after thyroidectomy. A third patient (family tree #1, Fig 1), as 
previously reported (6), died of coronary artery disease at age 
64 with nondetectable CT levels after provocative testing and 
no disease detected at autopsy. Of the remaining nine living 
patients, seven have had consistently normal test results since 
thyroidectomy, whereas two are considered to have meta-
static disease because of elevated CT levels basally or after 
provocative testing. 
The 22 family members thyroidectomized for early C-cell 
disease between 1972 and 1983 have been followed with annual 
or biannual testing for a mean of 11 years. Thyroidectomy led 
to a reduction in the peak serum CT after a provocative pen-
tagastrin test in each case. Nineteen of the 22 pafients have had 
normal test results. Three of the 22 patients have had clearly ab-
normal CT levels either basally or after a pentagastrin test on 
one or more occasions, although there was no other clinical evi-
dence of metastatic disease. Aliquots of the semm samples from 
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Fig 1—Pedigree of the J-kindred. The numbers 1 through 8 
shown for the second generation can be used to identify specific 
family members. For example, the propositus (marked with an 
arrow) is the second son of patient #4 (family tree #42) and his 
two sons would have family tree #421 and #422. A crossbar 
through the individual symbol indicates the patient is dead. The 
individual labeled O is the individual born in the 1880s listed as 
J in the pedigree ofthe large Swedish kindred shown in Fig 1 of 
the paper by Telenius-Berg et al (3). This family tree was pre-
pared according to March of Dimes criteria (Grendel Co, PO 
Box 733, Charleston, SC 29402). 
the three patients with abnormal test results and two others with 
borderline test results from the most recent round of testing were 
assayed in our standard CT RIA and the Nichols RIA (Table). A 
comparison of values shows that all of the sera considered to be 
abnormal in our assay gave normal values when tested in the 
Nichols assay. 
Parathyroid hormone measurements 
Parathyroid hyperplasia is a prominent manifestation of the 
MEN-2A syndrome (2,10-13), and previous studies in this 
family have demonstrated elevated parathyroid hormone (PTH) 
values in 40% of family members. In addition, parathyroid 
hyperplasia was found in ten of the 12 original members 
thyroidectomized between 1969 and 1971, and four of 12 had a 
history of renal stones (2). To determine whether clinically ap-
parent parathyroid disease preceded C-cell abnormalities, 
semm Ca levels were measured in all patients thyroidectomized 
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Table 
Comparison of Abnormal or Borderline Basal or 
Stimulated Calcitonin Values in Two Radioimmunoassays 
Family Tree Type of Assay 1 Assay 2 
Number Sample (calcitonin pg/mL) 
412 S 1,000 6 
313 S 890 8 
413 B 450 7 
422 B 630 5 
431 S 650 6 
Basal (B) or peak stimulated (S) serum calcitonin during a pentagastrin test. 
Assay 1 is our standard calcitonin radioimmunoassay, and assay 2 is the Nichols 
radioimmunoassay. 
for early C-cell abnormalities. The semm Ca concentration was 
within the normal range in all patients. The serum PTH con-
centration was normal in seven of nine patients in whom mea-
surements were made and was minimally elevated (< 5% above 
the upper limit of normal) in two patients. Postoperative PTH 
concentrations were available on 15 patients a mean of 9.9 years 
after thyroidectomy and were within the normal range for all pa-
tients. The semm Ca concentration has remained normal in all 
thyroidectomized patients with one exception. A 20-year-old 
woman (family tree #133, Fig 1) previously thyroidectomized 
(C-cell hyperplasia) with prethyroidectomy and postthyroid-
ectomy normocalcemia developed hypercalcemia (serum 
Ca 10.5 to 11.6 mg%) with mid-normal PTH concentrations. 
She also had symptoms of a pheochromocytoma and urine 
catecholamine abnormalities. Following bilateral pheo-
chromocytoma removal, her semm Ca normalized, and semm 
Ca and PTH measurements have remained normal (highest Ca 
value 10.3 mg) for nine years. We think it likely that the hyper-
calcemia was caused by the pheochromocytoma because of the 
immediate drop in the semm Ca after bilateral adrenalectomy. 
Adrenal medullary disease 
Nineteen patients have developed urine catecholamine abnor-
malities, which have resulted in ten bilateral adrenalectomies 
and eight unilateral adrenalectomies. The histologic lesion 
found at surgery in these patients was pheochromocytoma on a 
background of diffuse adrenal medullary hyperplasia in all adre-
nal glands except one in which adrenal medullary hyperplasia 
was noted. One patient (patient #7, Fig 1, who was thyroidec-
tomized before 1969) with abnormal urine catecholamine levels 
declined adrenal surgery because of widely metastatic 
MTC, Postmortem examination showed bilateral pheo-
chromocytomas. Another patient with proven MTC diagnosed 
before 1969 (patient #13, Fig 1) had been followed for 15 years 
with normal urine catecholamine levels. During the most recent 
testing, this 51-year-old woman was noted to have a 24-hour 
urine epinephrine two times the upper limit of normal. Because 
she was taking sympathomimetic dmgs and theophylline for al-
lergic lung disease, repeat urine catecholamine determinations 
with the patient off the medications were requested. She died 
suddenly before the repeat study could be done; a postmortem 
examination was not performed. Although the exact circum-
stances surrounding her death are unclear, the single urine 
catecholamine abnormality and her sudden death suggest the 
possibility of adrenal medullary disease. A third patient (family 
tree #1 , Fig I) with proven MTC, not included in these 19 
patients because of consistently normal urine catecholamine 
levels, died of well-documented coronary artery disease at 
age 64 and at autopsy was shown to have bilateral adrenal 
medullary hyperplasia (6). 
Four of the eight patients who underwent unilateral adrenalec-
tomy have required removal of the contralateral adrenal gland 
nine to 13 years after initial adrenalectomy because of the devel-
opment of urine catecholamine abnormalities and symptoms 
consistent with pheochromocytomas. Fig 2 shows longitudinal 
urine catecholamine measurements in one of these patients, 
which indicates that they may go for a prolonged period before 
requiring contralateral adrenalectomy. The other four patients 
with unilateral adrenalectomy have been followed for one, 11, 
15, and 17 years without developing symptoms of pheo-
chromocytomas or catecholamine abnormalities. 
Discussion 
Prospective screening for hereditary MTC 
The value of prospective screening in the early detection of C-
cell abnormalities has been established in this family (4,5) and 
several other kindreds (14-19). In each of our family members 
who developed disease, we were able to detect C-cell abnor-
malities before the development of local metastatic disease. In 
this family it appears that initiation of screening by the age of 
five years is adequate for detection of disease (20), but this may 
not be the case in all kindreds. In another large kindred with 
MEN-2A, one patient had an abnormal provocative CT test re-
sult on initial screening at age six with micrometastasis to local 
lymph nodes found at surgery (personal communication, 
Cynthia Torony). We have continued to recommend that screen-
ing start at age five in the J-kindred, but recognize that it 
might be necessary to initiate screening at an earlier age in 
other kindreds. 
The most important finding in this study is absence of detect-
able disease in 19 of 22 patients a mean of ten years after thy-
roidectomy for C-cell disease. In the patients with abnormal or 
borderline values in our RIA, we performed CT measurements 
using a more sensitive assay and found normal CT values. Stud-
ies are currently underway to assay these same samples in the 
two-site immunoradiometric assay described by Motte et al (21). 
Although the abnormal values in our standard RIA may be 
artifactual, a problem seen in all CT RIAs (7,22,23), it will be 
important to determine whether there is persistent or recurrent 
MTC because of the possible application of recently described 
microsurgical approaches to this group of patients (24). Al-
though we are optimistic at this time that thyroidectomy has re-
sulted in a cure for this group of patients, continued follow-up 
for an additional ten to 20 years will be required before such a 
conclusion can be firmly stated. 
Lack of evidence for parathyroid disease in early 
hereditary MTC 
Our studies show that semm Ca and PTH values are normal 
prior to and ten years after thyroidectomy. This is in contrast 
to earlier studies in this and other families with advanced. 
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untreated MTC in which clinically detectable parathyroid 
abnormalities have been found in 10% to 20% of affected family 
members (2,10-13). Our findings make it difficult to support 
the hypothesis that the C-cell abnormalities in this disease 
are the result of chronic hypercalcemia caused by hyper-
parathyroidism, a concept proposed earlier (2,10). The one case 
of hypercalcemia noted in the patients with early C-cell disease 
occurred in association with bilateral pheochromocytomas. 
Adrenal medullary disease 
Management of adrenal medullary disease in this syndrome is 
difficult, and the correct therapeutic approach is controversial. 
We have removed only those adrenal glands which had a pheo-
chromocytoma or distinct adrenal medullary enlargement 
demonstrable by angiography (before 1977), computed tomog-
raphy, or magnetic resonance imaging scanning. Each patient 
with documented unilateral disease was offered bilateral adre-
nalectomy at the time of the primary operation, but all declined. 
The contralateral adrenal gland is routinely examined at surgery 
and removed if the operative findings do not confirm the ra-
diologic evaluation. Of eight patients treated with unilateral 
adrenalectomy, it has been necessary to remove the contralateral 
adrenal gland in four patients an average of ten years after the 
primary operation; these results are not dissimilar to those 
described by other investigators (25). Other investigators have 
recommended bilateral adrenalectomy at the primary operation 
because of a family history of adrenal medullary malignancy 
(26-28) or because of concem about the risks of a second opera-
tion to remove the contralateral adrenal gland. We have not 
observed adrenal medullary malignancy in the J-kindred, and 
recognize that risks are associated with development of adrenal 
insufficiency following bilateral adrenal removal and that a dif-
ferent set of risks are associated with the removal of only a single 
adrenal gland. We have tried to minimize the total risk by com-
bining unilateral adrenalectomy, where appropriate, with yeariy 
postoperative urine catecholamine measurements. Continued 
follow-up is necessary before firm conclusions can be drawn 
about the correct management of adrenal medullary disease in 
this syndrome. 
Prospective screening for the several manifestations of 
MEN-2 has had a positive impact on the quality of life for this 
family and may prove, with continued follow-up, to have pro-
vided a cure for the malignant manifestations ofthe syndrome. 
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Fig 2 — Twenty-four hour urine epinephrine and the epi-
nephrine/norepinephrine ratio in a patient (family tree #22) 
who had a left adrenalectomy in 1974. After adrenalectomy, the 
24-hour urine epinephrine excretion arul the epinephrine!nor-
epinephrine ratio returned to normal for nine years before 
development of symptoms and objective demonstration of a 
pheochromocytoma led to the removal ofthe contralateral adre-
nal gland. Each point in the upper panel shows the results ofa 
single 24-hour urine collection. The points in the lower panel 
show the epinephrine/norepinephrine ratio calculated by divid-
ing the 24-hour excretion of epinephrine by the 24-hour ex-
cretion of norepinephrine as previously described (4,29). The 
dotted line in each panel shows the upper limit of normal for 
each measurement. 
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"Disease is very old and nothing about it has changed. It is we who change 
as we learn to recognize what was formerly imperceptible." 
J.M. Charcot (1825-1893) 
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